Curated News
By: NewsRamp Editorial Staff
June 18, 2026

LIXTE Biotech Pivots to Energy Storage with NOMAD Acquisition

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • LIXTE's acquisition of NOMAD positions it to capitalize on rising AI-driven electricity demand with mobile battery storage.
  • LIXTE will provide a $6.5 million loan to NOMAD for long-lead components and working capital before closing on July 1, 2026.
  • NOMAD's mobile battery systems provide rapid, reliable power to utilities and data centers, supporting critical infrastructure and AI growth.
  • LIXTE, a cancer drug developer, is acquiring a battery storage firm and will rename to NOMAD Power Solutions.

Impact - Why it Matters

This news matters because it highlights a bold strategic pivot by a clinical-stage biotech company into the rapidly growing energy storage sector, driven by the escalating power demands of AI and data centers. The acquisition of NOMAD positions LIXTE to address critical infrastructure needs, offering mobile, utility-grade battery storage that can be deployed quickly. For investors, this diversification could unlock new revenue streams and potentially higher valuations, while for the broader market, it signals increasing convergence between healthcare and clean energy technologies. The $6.5 million loan underscores the company's commitment to scaling NOMAD's manufacturing, which could accelerate the availability of reliable backup power for essential services.

Summary

In a transformative move, LIXTE Biotechnology Holdings (NASDAQ: LIXT) has announced that its previously disclosed acquisition of NOMAD Transportable Power Systems is expected to close on or about July 1, 2026. Ahead of the closing, LIXTE will provide a $6.5 million loan to NOMAD to support procurement of long-lead components, fund working capital, and help the company scale manufacturing against its growing order pipeline for deployable utility-grade battery energy storage systems. This strategic pivot positions LIXTE to capitalize on the surging demand for reliable power solutions driven by artificial intelligence infrastructure and high-density computing.

Upon completion of the transaction, the company expects to rename itself NOMAD Power Solutions, Inc. and adopt a new Nasdaq ticker symbol. NOMAD’s mobile, utility-grade battery energy storage platform is designed to provide rapid deployment and reliable power for utilities, industrial users, and data centers. The acquisition marks a significant shift for LIXTE, which is primarily a clinical-stage pharmaceutical and med-tech company focused on cancer drug development. LIXTE’s lead compound, LB-100, is a first-in-class PP2A inhibitor showing promise in enhancing chemotherapies and immunotherapies. Additionally, through its subsidiary Liora Technologies Europe Ltd., LIXTE is pioneering electronically controlled proton therapy systems for cancer treatment.

The deal underscores the growing convergence of energy and technology sectors, as the need for scalable and mobile power solutions becomes critical for emerging technologies like AI. The full press release is available at https://ibn.fm/s0uCh. For investors, the latest updates on LIXT can be found at https://ibn.fm/LIXT. This acquisition, facilitated by the communications platform MissionIR (part of IBN’s Dynamic Brand Portfolio), represents a bold diversification strategy that could redefine LIXTE’s future in the energy storage market.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, LIXTE Biotech Pivots to Energy Storage with NOMAD Acquisition

blockchain registration record for this content.